The United Kingdom and the United States have reached a key trade agreement that will preserve zero tariffs on British pharmaceutical shipments entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital exports will stay at zero for a timeframe of 36 months.
This agreement follows earlier threats to dramatically increase tariffs on branded pharmaceutical imports, with figures floated reaching one hundred percent.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," an announcement declared.
Economic Significance
Pharmaceuticals are one of the UK's most significant exports to the America, which is by far the largest market for large British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to last September, the UK exported medicines valued at £11.1bn to the US. This value accounted for 17.4% of all goods exports in that period.
"This deal safeguards jobs, stimulates capital expenditure and paves the way for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement involves several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Last year, rebates exceeded 20%.
Recent Tensions
This agreement takes place against a ongoing tension between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by assertions that US customers were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
